Publications

Export 113 results:
Sort by: Author Title [ Type  (Asc)] Year
Journal Article
Hegab, M. M., A. F. Abdelwahab, J. M. Rudolph, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, et al., "Corrigendum to “CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians” [Hum. Immunol. 77 (2016) 522–526] (S0198885916300684), (10.1016/j.humimm.2016.04.018))", Human Immunology, vol. 78, issue 7-8: Elsevier Inc., pp. 521, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hegab, M. M., A. F. Abdelwahab, J. M. Rudolph, A. E. - S. M. Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, and W. Abouraya, "Corrigendum to" CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians"[Hum. Immunol. 77 (2016) 522-526]", Human immunology, vol. 78, issue 7-8, pp. 521, 2017. Abstract
n/a
Vitale, A., F. Della Casa, G. Ragab, I. A. Almaghlouth, G. Lopalco, R. M. Pereira, S. Guerriero, M. Govoni, P. P. Sfikakis, R. Giacomelli, et al., "Development and implementation of the AIDA International Registry for patients with Behçet’s disease", Internal and Emergency Medicine: Springer Science and Business Media Deutschland GmbH, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Della Casa, F., A. Vitale, R. M. Pereira, S. Guerriero, G. Ragab, G. Lopalco, M. Cattalini, I. Mattioli, P. Parronchi, M. P. Paroli, et al., "Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis", Ophthalmology and Therapy, vol. 11, issue 2: Adis, pp. 887 - 897, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Casa, F. D., A. Vitale, S. Guerriero, J. Sota, R. Cimaz, G. Ragab, P. Ruscitti, R. M. R. Pereira, F. Minoia, E. Del Giudice, et al., "Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis", Ophthalmology and Therapy, vol. 11, issue 2: Adis, pp. 899 - 911, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Vitale, A., F. Della Casa, G. Lopalco, R. M. Pereira, P. Ruscitti, R. Giacomelli, G. Ragab, F. La Torre, E. Bartoloni, E. Del Giudice, et al., "Development and Implementation of the AIDA International Registry for Patients With Still's Disease", Frontiers in Medicine, vol. 9: Frontiers Media S.A., 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Della Casa, F., A. Vitale, G. Lopalco, P. Ruscitti, F. Ciccia, G. Emmi, M. Cattalini, E. Wiesik-Szewczyk, M. C. Maggio, B. Ogunjimi, et al., "Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases", Frontiers in Medicine, vol. 9: Frontiers Media S.A., 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Sota, J., D. Rigante, R. Cimaz, M. Cattalini, M. Frassi, R. Manna, L. L. Sicignano, E. Verrecchia, E. Aragona, and M. C. Maggio, "Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry", Rheumatology, 2021. Abstract
n/a
Sota, J., D. Rigante, R. Cimaz, M. Cattalini, M. Frassi, R. Manna, L. L. Sicignano, E. Verrecchia, E. Aragona, M. C. Maggio, et al., "Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: Observational study from the International AIDA Registry", Rheumatology (United Kingdom), vol. 60, issue 12: Oxford University Press, pp. 5705 - 5712, 2021. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Moawad, P., R. Shamma, D. Hassanein, G. Ragab, and O. El Zawahry, "Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome", European Journal of Ophthalmology, vol. 32, issue 1: SAGE Publications Ltd, pp. 673 - 679, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hussein, M., A. El-Hindawi, and G. Ragab, "Everolimus in Erdheim–Chester disease", The Egyptian Journal of Internal Medicine, vol. 25, issue 3, pp. 159 - 163, 2013/9/1. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ

A 43-year-old man presented with bony pains, repeated pathological fractures with overlying skin ulcerations, and forearm and chest wall swellings. Investigations led to the diagnosis of Erdheim–Chester disease. Treatment with low-dose prednisolone, oral everolimus, and zoledronic acid was started, with a marked improvement in his condition.

Hussein, M. A., A. El-Hindawi, and G. Ragab, "Everolimus in Erdheim–Chester disease", The Egyptian Journal of Internal Medicine, vol. 25, issue 3: SpringerOpen, pp. 159-163, 2013. Abstract
n/a
Ramos-Casals, M., A. L. Zignego, C. Ferri, P. Brito-Zerón, S. Retamozo, M. Casato, P. Lamprecht, A. Mangia, D. Saadoun, A. G. Tzioufas, et al., "Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection", Journal of Hepatology, vol. 66, no. 6: Elsevier {BV}, pp. 1282–1299, jun, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Ramos-Casals, M., A. L. Zignego, C. Ferri, P. Brito-Zeron, S. Retamozo, M. Casato, P. Lamprecht, A. Mangia, D. Saadoun, and A. G. Tzioufas, "Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection", Journal of Hepatology, vol. 66, issue 6: Elsevier, pp. 1282-1299, 2017. Abstract
n/a
M Fawzy, A Edrees, O. E. A. R. H. A. G., "Gastrointestinal manifestations in systemic lupus erythematosus", Lupus, 2016. Abstract
n/a
Fawzy, M., A. Edrees, H. Okasha, A. El Ashmaui, and G. Ragab, "Gastrointestinal manifestations in systemic lupus erythematosus", Lupus, vol. 25, issue 13: SAGE Publications Ltd, pp. 1456 - 1462, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Fawzy, M., A. Edrees, H. Okasha, A. El Ashmaui, and G. Ragab, "Gastrointestinal manifestations in systemic lupus erythematosus.", Lupus, 2016 Apr 6. Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multisystem involvement, including the gastrointestinal (GI) tract. There is a significant variation in the clinical presentation and severity of GI disorders. When GI symptoms present as the initial manifestation of SLE, there is likely to be a delay in the diagnosis. The cause of these GI manifestations in SLE may be the disease, or the side effects of medications, or infections. In this study we investigated the GI manifestations in a group of SLE patients. Our study was conducted on 40 SLE patients and 30 healthy controls to assess the prevalence of GI symptoms in SLE patients. The prevalence of gastrointestinal manifestations in our study was 42.5%. GI manifestations in our SLE patients were: acute abdominal pain (due to pleurisy and peritonitis), 6%; diffuse abdominal pain, 23.5%; epigastric pain, 29%; epigastric pain with vomiting, 23.5%; epigastric pain with chronic constipation, 6%; chronic constipation, 6%; and diffuse abdominal pain with bleeding per rectum, 6%. In our study, we found a higher incidence ofGiardiainfestation in SLE patients than in healthy controls, and 10% of these patients were asymptomatic. There was moreGiardiainfestation in patients with GI symptoms as compared with patients with no GI symptoms, with aPvalue of 0.009. In our study SLE patients with GI symptoms had a peak systolic velocity (cm/s) with a mean of 108.4 ± 32.1 standard deviation (SD) in the celiac Doppler study. Patients without GI symptoms had a peak systolic velocity with a mean of 111.9 ± 37.7 SD, meaning that our patients mostly had no evidence of celiac trunk stenosis, but there was significant difference between SLE patients without GI symptoms and controls, as the mean was higher in SLE patients than in the controls. Also, the celiac end diastolic velocity was higher in both groups of SLE patients with GI symptoms and those without GI symptoms, compared to controls.

Beshlawy, A. E., A. E. R. Zekri, M. S. Ramadan, Y. M. M. Selim, A. Abdel-Salam, M. T. Hegazy, L. Ragab, C. Gaggiano, L. Cantarini, and G. Ragab, "Genotype–phenotype associations in familial Mediterranean fever: a study of 500 Egyptian pediatric patients", Clinical Rheumatology, vol. 41, issue 5: Springer Science and Business Media Deutschland GmbH, pp. 1511 - 1521, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Ragab, G., M. Elshahaly, and T. Bardin, "Gout: An old disease in new perspective – A review", Journal of Advanced Research, vol. 8, issue 5: Elsevier B.V., pp. 495 - 511, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Ragab, G., M. Elshahaly, and T. Bardin, "Gout: An old disease in new perspective–A review", Journal of advanced research, vol. 8, issue 5: Elsevier, pp. 495-511, 2017. Abstract
n/a
Ragab, G., M. A. El-Ghobary, R. M. Elgohary, and others, "The importance of using ultrasonography in knee osteoarthritis", The Egyptian Journal of Internal Medicine, vol. 24, no. 3: Medknow Publications, pp. 93, 2012. Abstract
n/a
Ragab, G., M. A. El-Ghobary, and R. M. Elgohary, "The importance of using ultrasonography in knee osteoarthritis", The Egyptian Journal of Internal Medicine, vol. 24, issue 3: SpringerOpen, pp. 93-96, 2012. Abstract
n/a
Hegazy, M. T., W. R. Allam, M. A. Hussein, N. Zoheir, L. Quartuccio, S. F. El-Khamisy, and G. Ragab, "Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs", EBioMedicine, vol. 35: Elsevier, pp. 106-113, 2018. Abstract
n/a
Hegazy, M. T., W. R. Allam, M. A. Hussein, N. Zoheir, L. Quartuccio, S. F. El-Khamisy, G. Ragab, and M. C. C. the for the study of Vasculitis, "Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs", EBioMedicine, vol. 35: Elsevier B.V., pp. 106 - 113, 2018. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hegazy, M. T., W. R. Allam, M. A. Hussein, N. Zoheir, L. Quartuccio, S. F. El-Khamisy, and G. Ragab, "Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs.", EBioMedicine, vol. 35, pp. 106-113, 2018 Sep. Abstract

Mixed Cryoglobulinemic Vasculitis (MCV) is a prominent extra-hepatic manifestation of Hepatitis C virus (HCV) infection. HCV has been reported to cause B-cell disorders and genomic instability. Here, we investigated B-cell activation and genome stability in HCV-MCV patients receiving the direct antiviral agent, Sofosbuvir, at multiple centers in Egypt. Clinical manifestations in HCV-MCV patients were improved at the end of treatment (EOT), such as purpura (100%), articular manifestations (75%) and neuropathy (68%). Eighteen patients (56%) showed vasculitis relapse after EOT. BAFF and APRIL were higher at EOT and continued to increase one year following treatment onset. Chromosomal breaks were elevated at EOT compared to baseline levels and were sustained at 3 and 6 months post treatment. We report increased expression of DNA genome stability transcripts such as topoisomerase 1 and TDP1 in HCV-MCV patients after treatment, which continued to increase at 12 months from treatment onset. This data suggest that B-cell activation and DNA damage are important determinants of HCV-MCV treatment outcomes.

Ferri, C., M. Ramos-Casals, A. L. Zignego, L. Arcaini, D. Roccatello, A. Antonelli, D. Saadoun, A. C. Desbois, M. Sebastiani, and M. Casato, "International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement", Autoimmunity Reviews, vol. 15, issue 12: Elsevier, pp. 1145-1160, 2016. Abstract
n/a
Hamza, M. M. E., T. A. Macky, M. K. Sidky, G. Ragab, and M. M. Soliman, "Intravitreal infliximab in refractory uveitis in Behçet's disease: a safety and efficacy clinical study", Retina, vol. 36, issue 12: LWW, pp. 2399-2408, 2016. Abstract
n/a
Hamza, M. M. E., T. A. Macky, M. K. Sidky, G. Ragab, and M. M. Soliman, "Intravitreal infliximab in refractory uveitis in Behcet's disease: A safety and efficacy clinical study", Retina, vol. 36, issue 12: Lippincott Williams and Wilkins, pp. 2399 - 2408, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
, "Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey", Clinical rheumatology, vol. 36: Springer London, pp. 485-497, 2017. Abstract
n/a
Group, G. E. O. - R. A., C. Ramos-Remus, A. Ramirez-Gomez, V. Brambila-Barba, A. Barajas-Ochoa, J. D. Castillo-Ortiz, A. O. Adebajo, L. R. Espinoza, F. J. Aceves-Avila, J. M. Sánchez-González, et al., "Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey", Clinical Rheumatology, vol. 36, issue 3: Springer London, pp. 485 - 497, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy masquerading as systemic rheumatic diseases", JCR: Journal of Clinical Rheumatology, vol. 22, issue 5: LWW, pp. 264-271, 2016. Abstract
n/a
El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy Masquerading as Systemic Rheumatic Diseases", Journal of Clinical Rheumatology, vol. 22, issue 5: Lippincott Williams and Wilkins, pp. 264 - 271, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy Masquerading as Systemic Rheumatic Diseases.", Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, vol. 22, issue 5, pp. 264-71, 2016 Aug. Abstract

Rheumatologic manifestations not only are encountered in leprosy but also can be the first and even the sole presenting manifestation. The hallmark of leprosy is skin and peripheral nerve affection; however, it can affect a wide range of other organs, with the joints being the commonest. We have searched PubMed with the key words leprosy, arthritis, vasculitis, rheumatic diseases, and autoantibodies in a proper combination. Relevant studies were retrieved from scanning of their abstracts. The relevant references provided in these articles were also selected and reviewed. We summarize the clinical and laboratory manifestations that make leprosy masquerade as a systemic rheumatic disease. Moreover, we report 4 Egyptian patients who presented with rheumatologic manifestations, namely, arthritis and vasculitis that turned out to be leprosy related.

Cacoub, P., S. Nafa Si Ahmed, Y. Ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, and L. Quartuccio, "Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis", Clinical Gastroenterology and Hepatology, vol. 17, issue 3: WB Saunders, pp. 518-526, 2019. Abstract
n/a
Cacoub, P., S. N. Si ahmed, Y. ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, L. Quartuccio, et al., "Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis", Clinical Gastroenterology and Hepatology, vol. 17, issue 3: W.B. Saunders, pp. 518 - 526, 2019. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Goubran, H., J. Seghatchian, J. Radosevic, G. Ragab, and T. Burnouf, "The microbiome and transfusion in cancer patients", Transfusion and Apheresis ScienceTransfusion and Apheresis Science, vol. 56, issue 3: Elsevier, pp. 330 - 335, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ

Our microbiota is determined by many variables including ABO blood groups. The microbiota is not only confined to the gut and skin but is also recoverable from blood of healthy donors.The microbiota shape our immune system through cross reactivity with antigens, the expression of direct molecular patterns, the release of cytokines, the effects on nutrients and micronutrients and even through an interplay with epigenetics. It is likely, therefore, that a donor's microbiota could alter the antigenicity of blood and its components and potentially contribute to transfusion-related immune modulation [TRIM]. It could also potentially transmit infections. The recipient's microbiome contributes, on the other hand, to the tolerance to transfused blood, or to the development of transfusion reactions. Cancer patients are a particularly vulnerable population, often immunosuppressed with a significantly altered microbiota. They are more at risk for transmission of ?dormant? bacteria via blood transfusion. Furthermore, chemotherapy and radiation induce mucositis that likely results in significant translocation of gut microbiota and abnormal immune reactions to transfused blood. It is therefore relevant to revisit transfusion thresholds and consider transfusion-saving strategies in cancer patients.Our microbiota is determined by many variables including ABO blood groups. The microbiota is not only confined to the gut and skin but is also recoverable from blood of healthy donors.The microbiota shape our immune system through cross reactivity with antigens, the expression of direct molecular patterns, the release of cytokines, the effects on nutrients and micronutrients and even through an interplay with epigenetics. It is likely, therefore, that a donor's microbiota could alter the antigenicity of blood and its components and potentially contribute to transfusion-related immune modulation [TRIM]. It could also potentially transmit infections. The recipient's microbiome contributes, on the other hand, to the tolerance to transfused blood, or to the development of transfusion reactions. Cancer patients are a particularly vulnerable population, often immunosuppressed with a significantly altered microbiota. They are more at risk for transmission of ?dormant? bacteria via blood transfusion. Furthermore, chemotherapy and radiation induce mucositis that likely results in significant translocation of gut microbiota and abnormal immune reactions to transfused blood. It is therefore relevant to revisit transfusion thresholds and consider transfusion-saving strategies in cancer patients.

Goubran, H., J. Seghatchian, J. Radosevic, G. Ragab, and T. Burnouf, "The microbiome and transfusion in cancer patients", Transfusion and Apheresis Science, vol. 56, issue 3: Pergamon, pp. 330-335, 2017. Abstract
n/a
Goubran, H., J. Seghatchian, J. Radosevic, G. Ragab, and T. Burnouf, "The microbiome and transfusion in cancer patients", Transfusion and Apheresis Science, vol. 56, issue 3: Elsevier Ltd, pp. 330 - 335, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
REFAAT, M., A. M. Abdullatif, M. M. Hamza, T. A. Macky, M. - S. H. El-Agha, G. Ragab, and M. M. Soliman, "MONTHLY INTRAVITREAL INFLIXIMAB IN BEHÇET'S DISEASE ACTIVE POSTERIOR UVEITIS: A Long-Term Safety Study", Retina (Philadelphia, Pa.), vol. 41, issue 8: NLM (Medline), pp. 1739 - 1747, 2021. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Tourism